{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:57:26Z","timestamp":1790773046033,"version":"4.1.0"},"reference-count":141,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41585-026-01144-9","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T16:02:23Z","timestamp":1778083343000},"page":"654-671","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Oligometastatic prostate cancer \u2014 bridging the gap between localized and metastatic disease"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3345-4573","authenticated-orcid":false,"given":"Alexander","family":"Giesen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"den Hartog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasper","family":"Van Goubergen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kato","family":"Rans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcella","family":"Baldewijns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Gevaert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolien","family":"Goffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wouter","family":"Everaerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8676-7709","authenticated-orcid":false,"given":"Frank","family":"Claessens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gert","family":"De Meerleer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3195-9890","authenticated-orcid":false,"given":"Steven","family":"Joniau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"1144_CR1","unstructured":"Surveillance Epidemiology and End Results Program (SEER). Cancer Stat Facts: Prostate Cancer. https:\/\/seer.cancer.gov\/statfacts\/html\/prost.html (2024)."},{"key":"1144_CR2","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/JU.0000000000002757","volume":"208","author":"JA Eastham","year":"2022","unstructured":"Eastham, J. A. et al. Clinically localized prostate cancer: AUA\/ASTRO guideline, part I: introduction, risk assessment, staging, and risk-based management. J. Urol. 208, 10\u201318 (2022).","journal-title":"J. Urol."},{"key":"1144_CR3","unstructured":"EAU Guidelines. Presented at the EAU Annual Congress Madrid 2025. https:\/\/uroweb.org\/guidelines\/prostate-cancer (2026)."},{"key":"1144_CR4","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D\u2019Amico","year":"1998","unstructured":"D\u2019Amico, A. V. et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280, 969\u2013974 (1998).","journal-title":"JAMA"},{"key":"1144_CR5","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/pros.24041","volume":"80","author":"EC Dee","year":"2020","unstructured":"Dee, E. C. et al. Prostate cancer-specific mortality burden by risk group among men with localized disease: implications for research and clinical trial priorities. Prostate 80, 1128\u20131133 (2020).","journal-title":"Prostate"},{"key":"1144_CR6","unstructured":"National Comprehensive Cancer Network. Prostate Cancer (Version 2.2026) https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1459 (2025)."},{"issue":"Suppl. 1","key":"1144_CR7","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/S0022-510X(09)71300-0","volume":"287","author":"MP Sormani","year":"2009","unstructured":"Sormani, M. P. The Will Rogers phenomenon: the effect of different diagnostic criteria. J. Neurol. Sci. 287 (Suppl. 1), 46\u201349 (2009).","journal-title":"J. Neurol. Sci."},{"key":"1144_CR8","volume":"10","author":"MA Hoffmann","year":"2025","unstructured":"Hoffmann, M. A. et al. Pretreatment PSMA PET in prostate cancer patients without metastases by conventional imaging changes primary stage and treatment: a systematic review and meta-analysis. J. Surg. 10, 11247 (2025).","journal-title":"J. Surg."},{"key":"1144_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman, S. & Weichselbaum, R. R. Oligometastases. J. Clin. Oncol. 13, 8\u201310 (1995).","journal-title":"J. Clin. Oncol."},{"key":"1144_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/nrurol.2016.175","volume":"14","author":"JJ Tosoian","year":"2017","unstructured":"Tosoian, J. J. et al. Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations. Nat. Rev. Urol. 14, 15\u201325 (2017).","journal-title":"Nat. Rev. Urol."},{"key":"1144_CR11","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1002\/pros.23645","volume":"78","author":"E Francini","year":"2018","unstructured":"Francini, E. et al. Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC). Prostate 78, 889\u2013895 (2018).","journal-title":"Prostate"},{"key":"1144_CR12","doi-asserted-by":"publisher","first-page":"371.e11","DOI":"10.1016\/j.urolonc.2024.06.016","volume":"42","author":"M Wenzel","year":"2024","unstructured":"Wenzel, M. et al. Impact of time to metastatic disease onset and extent of disease volume across metastatic hormone-sensitive and castration-resistant prostate cancer. Urol. Oncol. 42, 371.e11\u2013371.e18 (2024).","journal-title":"Urol. Oncol."},{"key":"1144_CR13","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/j.eururo.2018.02.001","volume":"73","author":"G Gravis","year":"2018","unstructured":"Gravis, G. et al. Burden of metastatic castrate naive prostate cancer patients, to identify men more likely to benefit from early docetaxel: further analyses of CHAARTED and GETUG-AFU15 studies. Eur. Urol. 73, 847\u2013855 (2018).","journal-title":"Eur. Urol."},{"key":"1144_CR14","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1016\/j.eururo.2020.12.040","volume":"80","author":"MP Deek","year":"2021","unstructured":"Deek, M. P. et al. The mutational landscape of metastatic castration-sensitive prostate cancer: the spectrum theory revisited. Eur. Urol. 80, 632\u2013640 (2021).","journal-title":"Eur. Urol."},{"key":"1144_CR15","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.52546.3","volume":"10","author":"F Petrelli","year":"2021","unstructured":"Petrelli, F. et al. Better survival of patients with oligo- compared with polymetastatic cancers: a systematic review and meta-analysis of 173 studies. F1000Res 10, 423 (2021).","journal-title":"F1000Res"},{"key":"1144_CR16","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nrclinonc.2011.44","volume":"8","author":"RR Weichselbaum","year":"2011","unstructured":"Weichselbaum, R. R. & Hellman, S. Oligometastases revisited. Nat. Rev. Clin. Oncol. 8, 378\u2013382 (2011).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1144_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.clgc.2012.08.003","volume":"11","author":"P Berkovic","year":"2013","unstructured":"Berkovic, P. et al. Salvage stereotactic body radiotherapy for patients with limited prostate cancer metastases: deferring androgen deprivation therapy. Clin. Genitourin. Cancer 11, 27\u201332 (2013).","journal-title":"Clin. Genitourin. Cancer"},{"key":"1144_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1748-717X-9-135","volume":"9","author":"K Decaestecker","year":"2014","unstructured":"Decaestecker, K. et al. Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat. Oncol. 9, 135 (2014).","journal-title":"Radiat. Oncol."},{"key":"1144_CR19","unstructured":"(POPSTAR) A pilot study of patients with oligometastases from prostate cancer treated with stereotactic ablative body radiosurgery. ANZCTR https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview.aspx?id=363885 (2013)."},{"key":"1144_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-671","volume":"14","author":"K Decaestecker","year":"2014","unstructured":"Decaestecker, K. et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): study protocol for a randomized phase II trial. BMC Cancer 14, 671 (2014).","journal-title":"BMC Cancer"},{"key":"1144_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-017-3455-6","volume":"17","author":"N Radwan","year":"2017","unstructured":"Radwan, N. et al. A phase II randomized trial of observation versus stereotactic ablative radiation for oligometastatic prostate cancer (ORIOLE). BMC Cancer 17, 453 (2017).","journal-title":"BMC Cancer"},{"key":"1144_CR22","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2012.00172","volume":"2","author":"KA Ahmed","year":"2012","unstructured":"Ahmed, K. A. et al. Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front. Oncol. 2, 215 (2012).","journal-title":"Front. Oncol."},{"key":"1144_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-12-305","volume":"12","author":"DA Palma","year":"2012","unstructured":"Palma, D. A. et al. Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): study protocol for a randomized phase II trial. BMC Cancer 12, 305 (2012).","journal-title":"BMC Cancer"},{"key":"1144_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-018-4859-7","volume":"18","author":"R Olson","year":"2018","unstructured":"Olson, R. et al. Population-based phase II trial of stereotactic ablative radiotherapy (SABR) for up to 5 oligometastases: SABR-5. BMC Cancer 18, 954 (2018).","journal-title":"BMC Cancer"},{"key":"1144_CR25","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-023-02268-3","volume":"41","author":"G Francolini","year":"2023","unstructured":"Francolini, G. et al. PERSIAN trial (NCT05717660): an ongoing randomized trial testing androgen deprivation therapy, apalutamide and stereotactic body radiotherapy. An alternative \u201ctriplet\u201d for oligometastatic hormone sensitive prostate cancer patients. Med. Oncol. 41, 39 (2023).","journal-title":"Med. Oncol."},{"key":"1144_CR26","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","volume":"9","author":"C Tang","year":"2023","unstructured":"Tang, C. et al. Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the extend phase 2 randomized clinical trial. JAMA Oncol. 9, 825\u2013834 (2023).","journal-title":"JAMA Oncol."},{"key":"1144_CR27","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1056\/NEJMoa1503747","volume":"373","author":"CJ Sweeney","year":"2015","unstructured":"Sweeney, C. J. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N. Engl. J. Med. 373, 737\u2013746 (2015).","journal-title":"N. Engl. J. Med."},{"key":"1144_CR28","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","volume":"392","author":"CC Parker","year":"2018","unstructured":"Parker, C. C. et al. Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet 392, 2353\u20132366 (2018).","journal-title":"Lancet"},{"key":"1144_CR29","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos, C. E. et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J. Clin. Oncol. 36, 1080\u20131087 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1144_CR30","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1001\/jamaoncol.2020.7857","volume":"7","author":"A Ali","year":"2021","unstructured":"Ali, A. et al. Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial. JAMA Oncol. 7, 555\u2013563 (2021).","journal-title":"JAMA Oncol."},{"key":"1144_CR31","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips, R. et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the oriole phase 2 randomized clinical trial. JAMA Oncol. 6, 650\u2013659 (2020).","journal-title":"JAMA Oncol."},{"key":"1144_CR32","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost, P. et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J. Clin. Oncol. 36, 446\u2013453 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1144_CR33","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","volume":"26","author":"G Marvaso","year":"2025","unstructured":"Marvaso, G. et al. ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial. Lancet Oncol. 26, 300\u2013311 (2025).","journal-title":"Lancet Oncol."},{"key":"1144_CR34","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02264379 (2023)."},{"key":"1144_CR35","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1002\/ijc.35052","volume":"155","author":"AW See","year":"2024","unstructured":"See, A. W. et al. Five-year outcomes of fractionated stereotactic body radiotherapy for oligometastatic prostate cancer from the TRANSFORM phase II trial. Int. J. Cancer 155, 1248\u20131256 (2024).","journal-title":"Int. J. Cancer"},{"key":"1144_CR36","doi-asserted-by":"publisher","first-page":"5009","DOI":"10.1200\/JCO.2025.43.16_suppl.5009","volume":"43","author":"BM Priv\u00e9","year":"2025","unstructured":"Priv\u00e9, B. M. et al. Lutetium-177-PSMA-617 in oligo-metastatic hormone sensitive prostate cancer (BULLSEYE trial). J. Clin. Oncol. 43, 5009 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1144_CR37","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-020-07386-z","volume":"20","author":"BM Priv\u00e9","year":"2020","unstructured":"Priv\u00e9, B. M. et al. Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trial. BMC Cancer 20, 884 (2020).","journal-title":"BMC Cancer"},{"key":"1144_CR38","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04641078 (2024)."},{"key":"1144_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-022-10374-0","volume":"22","author":"K Rans","year":"2022","unstructured":"Rans, K. et al. SPARKLE: a new spark in treating oligorecurrent prostate cancer: adding systemic treatment to stereotactic body radiotherapy or metastasectomy: key to long-lasting event-free survival?. BMC Cancer 22, 1294 (2022).","journal-title":"BMC Cancer"},{"key":"1144_CR40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.6_suppl.TPS283","volume":"41","author":"BF Koontz","year":"2023","unstructured":"Koontz, B. F. et al. NRG-GU011: a phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN). J. Clin. Oncol. 41, TPS283 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1144_CR41","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.eururo.2024.01.021","volume":"85","author":"J Nikitas","year":"2024","unstructured":"Nikitas, J. et al. Systemic and tumor-directed therapy for oligorecurrent metastatic prostate cancer (SATURN): primary endpoint results from a phase 2 clinical trial. Eur. Urol. 85, 517\u2013520 (2024).","journal-title":"Eur. Urol."},{"key":"1144_CR42","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-5977-6","volume":"19","author":"DA Palma","year":"2019","unstructured":"Palma, D. A. et al. Stereotactic ablative radiotherapy for the comprehensive treatment of 4-10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer 19, 816 (2019).","journal-title":"BMC Cancer"},{"key":"1144_CR43","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06563388 (2026)."},{"key":"1144_CR44","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06430411 (2024)."},{"key":"1144_CR45","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1200\/JCO.22.00644","volume":"40","author":"MP Deek","year":"2022","unstructured":"Deek, M. P. et al. Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: analysis of STOMP and ORIOLE trials. J. Clin. Oncol. 40, 3377\u20133382 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1144_CR46","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/s41391-021-00484-4","volume":"25","author":"P Sutera","year":"2022","unstructured":"Sutera, P. et al. Definitions of disease burden across the spectrum of metastatic castration-sensitive prostate cancer: comparison by disease outcomes and genomics. Prostate Cancer Prostatic Dis. 25, 713\u2013719 (2022).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1144_CR47","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.euo.2024.05.011","volume":"8","author":"P Sutera","year":"2025","unstructured":"Sutera, P. et al. Genomic determinants associated with modes of progression and patterns of failure in metachronous oligometastatic castration-sensitive prostate cancer. Eur. Urol. Oncol. 8, 111\u2013118 (2025).","journal-title":"Eur. Urol. Oncol."},{"key":"1144_CR48","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.eururo.2023.03.001","volume":"84","author":"KM Chow","year":"2023","unstructured":"Chow, K. M. et al. Head-to-head comparison of the diagnostic accuracy of prostate-specific membrane antigen positron emission tomography and conventional imaging modalities for initial staging of intermediate- to high-risk prostate cancer: a systematic review and meta-analysis. Eur. Urol. 84, 36\u201348 (2023).","journal-title":"Eur. Urol."},{"key":"1144_CR49","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1007\/s00259-021-05245-y","volume":"48","author":"F Ceci","year":"2021","unstructured":"Ceci, F. et al. E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET. Eur. J. Nucl. Med. Mol. Imaging 48, 1626\u20131638 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1144_CR50","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12253-008-9104-2","volume":"15","author":"S Mannweiler","year":"2009","unstructured":"Mannweiler, S. et al. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol. Oncol. Res. 15, 167\u2013172 (2009).","journal-title":"Pathol. Oncol. Res."},{"key":"1144_CR51","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1016\/S0140-6736(20)30314-7","volume":"395","author":"MS Hofman","year":"2020","unstructured":"Hofman, M. S. et al. Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. Lancet 395, 1208\u20131216 (2020).","journal-title":"Lancet"},{"key":"1144_CR52","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41391-023-00755-2","volume":"27","author":"S Huang","year":"2024","unstructured":"Huang, S. et al. Comparison of 18F-based PSMA radiotracers with [68Ga]Ga-PSMA-11 in PET\/CT imaging of prostate cancer-a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 27, 654\u2013664 (2024).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"1144_CR53","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00259-021-05520-y","volume":"49","author":"DA Pattison","year":"2022","unstructured":"Pattison, D. A. et al. Prospective intra-individual blinded comparison of [18F]PSMA-1007 and [68Ga]Ga-PSMA-11 PET\/CT imaging in patients with confirmed prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 49, 763\u2013776 (2022).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1144_CR54","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert, R. et al. Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur. Urol. 83, 405\u2013412 (2023).","journal-title":"Eur. Urol."},{"key":"1144_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17050841","volume":"17","author":"MA Hoffmann","year":"2025","unstructured":"Hoffmann, M. A. et al. Management based on pretreatment PSMA PET of patients with localized high-risk prostate cancer part 2: prediction of recurrence-a systematic review and meta-analysis. Cancers 17, 841 (2025).","journal-title":"Cancers"},{"key":"1144_CR56","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1016\/j.euo.2024.04.003","volume":"7","author":"K Rans","year":"2024","unstructured":"Rans, K. et al. Progression-directed therapy in oligoprogressive castration-resistant prostate cancer: final results from the prospective, single-arm, phase 2 MEDCARE trial. Eur. Urol. Oncol. 7, 1441\u20131450 (2024).","journal-title":"Eur. Urol. Oncol."},{"key":"1144_CR57","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S2666-1683(24)01252-7","volume":"69","author":"G De Meerleer","year":"2024","unstructured":"De Meerleer, G., Joniau, S., Goffin, K., Den Hartog, J. & Rans, K. P125 long-term outcomes of the MEDCARE phase 2 trial: progression-directed therapy in oligoprogressive castration-resistant prostate cancer. Eur. Urol. Open Sci. 69, 157\u2013158 (2024).","journal-title":"Eur. Urol. Open Sci."},{"key":"1144_CR58","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.eururo.2023.04.025","volume":"84","author":"P Sutera","year":"2023","unstructured":"Sutera, P. et al. Clinical and genomic differences between advanced molecular imaging-detected and conventional imaging-detected metachronous oligometastatic castration-sensitive prostate cancer. Eur. Urol. 84, 531\u2013535 (2023).","journal-title":"Eur. Urol."},{"key":"1144_CR59","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.ajpath.2011.03.028","volume":"179","author":"AP Putzke","year":"2011","unstructured":"Putzke, A. P. et al. Metastatic progression of prostate cancer and e-cadherin regulation by zeb1 and SRC family kinases. Am. J. Pathol. 179, 400\u2013410 (2011).","journal-title":"Am. J. Pathol."},{"key":"1144_CR60","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.1158\/0008-5472.CAN-24-0890","volume":"84","author":"R Shrestha","year":"2024","unstructured":"Shrestha, R. et al. An atlas of accessible chromatin in advanced prostate cancer reveals the epigenetic evolution during tumor progression. Cancer Res. 84, 3086\u20133100 (2024).","journal-title":"Cancer Res."},{"key":"1144_CR61","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17101638","volume":"17","author":"MR Patysheva","year":"2025","unstructured":"Patysheva, M. R., Fedorenko, A. A., Khozyainova, A. A., Denisov, E. V. & Gerashchenko, T. S. Immune evasion in cancer metastasis: an unappreciated role of monocytes. Cancers 17, 1638\u00a0(2025).","journal-title":"Cancers"},{"key":"1144_CR62","doi-asserted-by":"publisher","first-page":"6139","DOI":"10.1038\/s41388-020-01432-7","volume":"39","author":"Q Wei","year":"2020","unstructured":"Wei, Q., Qian, Y., Yu, J. & Wong, C. C. Metabolic rewiring in the promotion of cancer metastasis: mechanisms and therapeutic implications. Oncogene 39, 6139\u20136156 (2020).","journal-title":"Oncogene"},{"key":"1144_CR63","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1038\/sj.bjc.6602851","volume":"93","author":"J Domingo-Domenech","year":"2005","unstructured":"Domingo-Domenech, J. et al. Activation of nuclear factor-\u03baB in human prostate carcinogenesis and association to biochemical relapse. Br. J. Cancer 93, 1285\u20131294 (2005).","journal-title":"Br. J. Cancer"},{"key":"1144_CR64","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1242\/jcs.000455","volume":"121","author":"MJ Wheelock","year":"2008","unstructured":"Wheelock, M. J., Shintani, Y., Maeda, M., Fukumoto, Y. & Johnson, K. R. Cadherin switching. J. Cell Sci. 121, 727\u2013735 (2008).","journal-title":"J. Cell Sci."},{"key":"1144_CR65","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3892\/ijo.2015.3270","volume":"48","author":"M Wang","year":"2016","unstructured":"Wang, M. et al. N-cadherin promotes epithelial-mesenchymal transition and cancer stem cell-like traits via ErbB signaling in prostate cancer cells. Int. J. Oncol. 48, 595\u2013606 (2016).","journal-title":"Int. J. Oncol."},{"key":"1144_CR66","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1038\/onc.2010.102","volume":"29","author":"E S\u00e1nchez-Till\u00f3","year":"2010","unstructured":"S\u00e1nchez-Till\u00f3, E. et al. ZEB1 represses E-cadherin and induces an EMT by recruiting the SWI\/SNF chromatin-remodeling protein BRG1. Oncogene 29, 3490\u20133500 (2010).","journal-title":"Oncogene"},{"key":"1144_CR67","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1038\/35000034","volume":"2","author":"E Batlle","year":"2000","unstructured":"Batlle, E. et al. The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol. 2, 84\u201389 (2000).","journal-title":"Nat. Cell Biol."},{"key":"1144_CR68","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1038\/s41416-021-01435-5","volume":"125","author":"F Ahmad","year":"2021","unstructured":"Ahmad, F., Cherukuri, M. K. & Choyke, P. L. Metabolic reprogramming in prostate cancer. Br. J. Cancer 125, 1185\u20131196 (2021).","journal-title":"Br. J. Cancer"},{"key":"1144_CR69","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1038\/ncb2172","volume":"13","author":"P Jiang","year":"2011","unstructured":"Jiang, P. et al. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat. Cell Biol. 13, 310\u2013316 (2011).","journal-title":"Nat. Cell Biol."},{"key":"1144_CR70","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1016\/j.celrep.2014.07.053","volume":"8","author":"L Wang","year":"2014","unstructured":"Wang, L. et al. Hexokinase 2-mediated Warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth. Cell Rep. 8, 1461\u20131474 (2014).","journal-title":"Cell Rep."},{"key":"1144_CR71","doi-asserted-by":"publisher","unstructured":"Mout, L. et al. Genetic and epigenetic reprogramming of transposable elements drives ecDNA-mediated metastatic prostate cancer. Preprint at\u00a0bioRxiv https:\/\/doi.org\/10.1101\/2025.08.08.668693 (2025).","DOI":"10.1101\/2025.08.08.668693"},{"key":"1144_CR72","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.1038\/s41588-018-0165-1","volume":"50","author":"CM Bielski","year":"2018","unstructured":"Bielski, C. M. et al. Genome doubling shapes the evolution and prognosis of advanced cancers. Nat. Genet. 50, 1189\u20131195 (2018).","journal-title":"Nat. Genet."},{"key":"1144_CR73","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0124292","volume":"10","author":"Z Guo","year":"2015","unstructured":"Guo, Z. et al. Somatostatin derivate (smsDX) attenuates the TAM-stimulated proliferation, migration and invasion of prostate cancer via NF-\u03baB regulation. PLoS ONE 10, e0124292 (2015).","journal-title":"PLoS ONE"},{"key":"1144_CR74","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1038\/ng.3315","volume":"47","author":"PC Boutros","year":"2015","unstructured":"Boutros, P. C. et al. Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat. Genet. 47, 736\u2013745 (2015).","journal-title":"Nat. Genet."},{"key":"1144_CR75","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1016\/j.cell.2018.03.029","volume":"173","author":"SMG Espiritu","year":"2018","unstructured":"Espiritu, S. M. G. et al. The evolutionary landscape of localized prostate cancers drives clinical aggression. Cell 173, 1003\u20131013.e15 (2018).","journal-title":"Cell"},{"key":"1144_CR76","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1016\/S1470-2045(14)71021-6","volume":"15","author":"E Lalonde","year":"2014","unstructured":"Lalonde, E. et al. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. Lancet Oncol. 15, 1521\u20131532 (2014).","journal-title":"Lancet Oncol."},{"key":"1144_CR77","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/nature20788","volume":"541","author":"M Fraser","year":"2017","unstructured":"Fraser, M. et al. Genomic hallmarks of localized, non-indolent prostate cancer. Nature 541, 359\u2013364 (2017).","journal-title":"Nature"},{"key":"1144_CR78","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41588-025-02128-y","volume":"57","author":"X Xu","year":"2025","unstructured":"Xu, X. et al. The landscape of N6-methyladenosine in localized primary prostate cancer. Nat. Genet. 57, 934\u2013948 (2025).","journal-title":"Nat. Genet."},{"key":"1144_CR79","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.euo.2023.02.010","volume":"6","author":"U Milenkovic","year":"2023","unstructured":"Milenkovic, U. et al. Predictors of recurrence after metastasis-directed therapy in oligorecurrent prostate cancer following radical prostatectomy. Eur. Urol. Oncol. 6, 582\u2013589 (2023).","journal-title":"Eur. Urol. Oncol."},{"key":"1144_CR80","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s43018-023-00692-y","volume":"5","author":"EW Warner","year":"2024","unstructured":"Warner, E. W. et al. Multiregion sampling of de novo metastatic prostate cancer reveals complex polyclonality and augments clinical genotyping. Nat. Cancer 5, 114\u2013130 (2024).","journal-title":"Nat. Cancer"},{"key":"1144_CR81","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41568-023-00648-5","volume":"24","author":"M Fujii","year":"2024","unstructured":"Fujii, M., Sekine, S. & Sato, T. Decoding the basis of histological variation in human cancer. Nat. Rev. Cancer 24, 141\u2013158 (2024).","journal-title":"Nat. Rev. Cancer"},{"key":"1144_CR82","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/pros.24629","volume":"84","author":"T Hoang","year":"2024","unstructured":"Hoang, T. et al. TP53 structure-function relationships in metastatic castrate-sensitive prostate cancer and the impact of APR-246 treatment. Prostate 84, 87\u201399 (2024).","journal-title":"Prostate"},{"key":"1144_CR83","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1038\/s41416-023-02485-7","volume":"130","author":"DE O\u2019Malley","year":"2024","unstructured":"O\u2019Malley, D. E. et al. Acquired copy number variation in prostate tumours: a review of common somatic copy number alterations, how they are formed and their clinical utility. Br. J. Cancer 130, 347\u2013357 (2024).","journal-title":"Br. J. Cancer"},{"key":"1144_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-022-01080-4","volume":"14","author":"E Grist","year":"2022","unstructured":"Grist, E. et al. Accumulation of copy number alterations and clinical progression across advanced prostate cancer. Genome Med. 14, 102 (2022).","journal-title":"Genome Med."},{"key":"1144_CR85","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.ijrobp.2022.12.006","volume":"115","author":"P Sutera","year":"2023","unstructured":"Sutera, P. et al. WNT pathway mutations in metachronous oligometastatic castration-sensitive prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 115, 1095\u20131101 (2023).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1144_CR86","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02854","volume":"10","author":"E Martin-Orozco","year":"2019","unstructured":"Martin-Orozco, E., Sanchez-Fernandez, A., Ortiz-Parra, I. & Ayala-San Nicolas, M. WNT signaling in tumors: the way to evade drugs and immunity. Front. Immunol. 10, 2854 (2019).","journal-title":"Front. Immunol."},{"key":"1144_CR87","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1038\/nrurol.2017.144","volume":"14","author":"V Murillo-Garz\u00f3n","year":"2017","unstructured":"Murillo-Garz\u00f3n, V. & Kypta, R. WNT signalling in prostate cancer. Nat. Rev. Urol. 14, 683\u2013696 (2017).","journal-title":"Nat. Rev. Urol."},{"key":"1144_CR88","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/j.euo.2021.10.005","volume":"4","author":"K Van der Eecken","year":"2021","unstructured":"Van der Eecken, K. et al. Tissue- and blood-derived genomic biomarkers for metastatic hormone-sensitive prostate cancer: a systematic review. Eur. Urol. Oncol. 4, 914\u2013923 (2021).","journal-title":"Eur. Urol. Oncol."},{"key":"1144_CR89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0028650","volume":"6","author":"YA Lussier","year":"2011","unstructured":"Lussier, Y. A. et al. MicroRNA expression characterizes oligometastasis(es). PLoS ONE 6, e28650 (2011).","journal-title":"PLoS ONE"},{"key":"1144_CR90","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133278","volume":"13","author":"G Corrao","year":"2021","unstructured":"Corrao, G. et al. Exploring miRNA signature and other potential biomarkers for oligometastatic prostate cancer characterization: the biological challenge behind clinical practice. a narrative review. Cancers 13, 3278\u00a0(2021).","journal-title":"Cancers"},{"key":"1144_CR91","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1007\/s00345-018-2609-8","volume":"37","author":"B Dhondt","year":"2019","unstructured":"Dhondt, B. et al. Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time. World J. Urol. 37, 2557\u20132564 (2019).","journal-title":"World J. Urol."},{"key":"1144_CR92","doi-asserted-by":"publisher","first-page":"B031","DOI":"10.1158\/1557-3265.TARGETEDTHERAP-B031","volume":"31","author":"JH Wang","year":"2025","unstructured":"Wang, J. H. et al. Abstract B031: proteomic profiling of oligometastatic castration-sensitive prostate cancer treated with stereotactic ablative radiotherapy. Clin. Cancer Res. 31, B031 (2025).","journal-title":"Clin. Cancer Res."},{"key":"1144_CR93","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/j.euo.2023.07.014","volume":"7","author":"P Sutera","year":"2024","unstructured":"Sutera, P. et al. Identification of a predictive genomic biomarker for prostate-directed therapy in synchronous low-volume metastatic castration-sensitive prostate cancer. Eur. Urol. Oncol. 7, 241\u2013247 (2024).","journal-title":"Eur. Urol. Oncol."},{"key":"1144_CR94","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.ijrobp.2022.12.035","volume":"116","author":"PL Nguyen","year":"2023","unstructured":"Nguyen, P. L. et al. Analysis of a biopsy-based genomic classifier in high-risk prostate cancer: meta-analysis of the NRG oncology\/radiation therapy oncology group 9202, 9413, and 9902 phase 3 randomized trials. Int. J. Radiat. Oncol. Biol. Phys. 116, 521\u2013529 (2023).","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"1144_CR95","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1200\/JCO.2017.74.2940","volume":"36","author":"DE Spratt","year":"2018","unstructured":"Spratt, D. E. et al. Development and validation of a novel integrated clinical-genomic risk group classification for localized prostate cancer. J. Clin. Oncol. 36, 581\u2013590 (2018).","journal-title":"J. Clin. Oncol."},{"key":"1144_CR96","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1001\/jamaoncol.2020.7671","volume":"7","author":"FY Feng","year":"2021","unstructured":"Feng, F. Y. et al. Validation of a 22-gene genomic classifier in patients with recurrent prostate cancer: an ancillary study of the NRG\/RTOG 9601 randomized clinical trial. JAMA Oncol. 7, 544\u2013552 (2021).","journal-title":"JAMA Oncol."},{"key":"1144_CR97","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06212583 (2023)."},{"key":"1144_CR98","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.euo.2019.02.001","volume":"2","author":"E Ventimiglia","year":"2019","unstructured":"Ventimiglia, E. et al. A systematic review of the role of definitive local treatment in patients with clinically lymph node-positive prostate cancer. Eur. Urol. Oncol. 2, 294\u2013301 (2019).","journal-title":"Eur. Urol. Oncol."},{"key":"1144_CR99","doi-asserted-by":"publisher","first-page":"3939","DOI":"10.1200\/JCO.2013.54.7893","volume":"32","author":"F Abdollah","year":"2014","unstructured":"Abdollah, F. et al. Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer. J. Clin. Oncol. 32, 3939\u20133947 (2014).","journal-title":"J. Clin. Oncol."},{"key":"1144_CR100","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bju.14241","volume":"123","author":"M Gupta","year":"2019","unstructured":"Gupta, M., Patel, H. D., Schwen, Z. R., Tran, P. T. & Partin, A. W. Adjuvant radiation with androgen-deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit. BJU Int. 123, 252\u2013260 (2019).","journal-title":"BJU Int."},{"key":"1144_CR101","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.euf.2022.09.005","volume":"9","author":"V Fonteyne","year":"2023","unstructured":"Fonteyne, V. et al. Evaluating the impact of prostate only versus pelvic radiotherapy for pathological node-positive prostate cancer: first results from the multicenter phase 3 PROPER trial. Eur. Urol. Focus. 9, 317\u2013324 (2023).","journal-title":"Eur. Urol. Focus."},{"key":"1144_CR102","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.eururo.2020.01.033","volume":"77","author":"L Moris","year":"2020","unstructured":"Moris, L. et al. Benefits and risks of primary treatments for high-risk localized and locally advanced prostate cancer: an international multidisciplinary systematic review [Formula presented]. Eur. Urol. 77, 614\u2013627 (2020).","journal-title":"Eur. Urol."},{"key":"1144_CR103","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","volume":"76","author":"S Burdett","year":"2019","unstructured":"Burdett, S. et al. Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis. Eur. Urol. 76, 115\u2013124 (2019).","journal-title":"Eur. Urol."},{"key":"1144_CR104","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/j.eururo.2013.11.012","volume":"65","author":"SH Culp","year":"2014","unstructured":"Culp, S. H., Schellhammer, P. F. & Williams, M. B. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur. Urol. 65, 1058\u20131066 (2014).","journal-title":"Eur. Urol."},{"key":"1144_CR105","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"LMS Boev\u00e9","year":"2019","unstructured":"Boev\u00e9, L. M. S. et al. Effect on survival of androgen deprivation therapy alone compared to androgen deprivation therapy combined with concurrent radiation therapy to the prostate in patients with primary bone metastatic prostate cancer in a prospective randomised clinical trial: data from the HORRAD trial. Eur. Urol. 75, 410\u2013418 (2019).","journal-title":"Eur. Urol."},{"key":"1144_CR106","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(24)01865-8","volume":"404","author":"A Bossi","year":"2024","unstructured":"Bossi, A. et al. Efficacy and safety of prostate radiotherapy in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u2008\u00d7\u20082 factorial design. Lancet 404, 2065\u20132076 (2024).","journal-title":"Lancet"},{"key":"1144_CR107","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003998","volume":"19","author":"CC Parker","year":"2022","unstructured":"Parker, C. C. et al. Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: long-term results from the STAMPEDE randomised controlled trial. PLoS Med. 19, e1003998 (2022).","journal-title":"PLoS Med."},{"key":"1144_CR108","doi-asserted-by":"publisher","DOI":"10.1186\/s13014-024-02544-0","volume":"19","author":"KKM Kramer","year":"2024","unstructured":"Kramer, K. K. M. et al. Cost-effectiveness analysis of additional local prostate radio therapy in metastatic prostate cancer from a Medicare perspective. Radiat. Oncol. 19, 167 (2024).","journal-title":"Radiat. Oncol."},{"key":"1144_CR109","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1177\/03915603211036631","volume":"89","author":"H Shemshaki","year":"2022","unstructured":"Shemshaki, H., Al-Mamari, S. A., Geelani, I. A. & Kumar, S. Cytoreductive radical prostatectomy versus systemic therapy and radiation therapy in metastatic prostate cancer: a systematic review and meta-analysis. Urologia 89, 16\u201330 (2022).","journal-title":"Urologia"},{"key":"1144_CR110","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1111\/bju.15553","volume":"129","author":"S Buelens","year":"2022","unstructured":"Buelens, S. et al. Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study). BJU Int. 129, 699\u2013707 (2022).","journal-title":"BJU Int."},{"key":"1144_CR111","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.euo.2022.06.001","volume":"5","author":"B Dai","year":"2022","unstructured":"Dai, B. et al. Combination of androgen deprivation therapy with radical local therapy versus androgen deprivation therapy alone for newly diagnosed oligometastatic prostate cancer: a phase II randomized controlled trial. Eur. Urol. Oncol. 5, 519\u2013525 (2022).","journal-title":"Eur. Urol. Oncol."},{"key":"1144_CR112","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.euo.2022.07.005","volume":"5","author":"P Blanchard","year":"2022","unstructured":"Blanchard, P. & Vickers, A. J. Prostatectomy in patients with oligometastatic hormone-sensitive prostate cancer? Not yet. Eur. Urol. Oncol. 5, 526\u2013527 (2022).","journal-title":"Eur. Urol. Oncol."},{"key":"1144_CR113","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1111\/bju.15669","volume":"130","author":"P Sooriakumaran","year":"2022","unstructured":"Sooriakumaran, P. et al. Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: the testing radical prostatectomy in men with prostate cancer and oligo-metastases to the bone (TRoMbone) trial. BJU Int. 130, 43\u201353 (2022).","journal-title":"BJU Int."},{"key":"1144_CR114","doi-asserted-by":"publisher","unstructured":"Graefen, M. et al. Best systemic therapy with or without radical prostatectomy in the management of men with oligometastatic prostate cancer: the RAMPP randomised controlled trial. Eur Urol. https:\/\/doi.org\/10.1016\/j.eururo.2025.09.4144 (2025).","DOI":"10.1016\/j.eururo.2025.09.4144"},{"key":"1144_CR115","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT02971358 (2025)."},{"key":"1144_CR116","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03456843 (2026)."},{"key":"1144_CR117","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03678025 (2025)."},{"key":"1144_CR118","doi-asserted-by":"publisher","first-page":"2830","DOI":"10.1200\/JCO.20.00818","volume":"38","author":"DA Palma","year":"2020","unstructured":"Palma, D. A. et al. Stereotactic ablative radiotherapy for the comprehensive treatment of oligometastatic cancers: long-term results of the SABR-COMET phase II randomized trial. J. Clin. Oncol. 38, 2830\u20132838 (2020).","journal-title":"J. Clin. Oncol."},{"key":"1144_CR119","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1200\/JCO.2025.43.5_suppl.15","volume":"43","author":"C Tang","year":"2025","unstructured":"Tang, C. et al. World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): an analysis from the X-MET collaboration. J. Clin. Oncol. 43, 15 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1144_CR120","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1200\/JCO-25-00131","volume":"43","author":"JH Wang","year":"2025","unstructured":"Wang, J. H. et al. Outcomes of radium-223 and stereotactic ablative radiotherapy versus stereotactic ablative radiotherapy for oligometastatic prostate cancers: the RAVENS phase II randomized trial. J. Clin. Oncol. 43, 2059\u20132068 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1144_CR121","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/bju.15988","volume":"132","author":"TM Ma","year":"2023","unstructured":"Ma, T. M. et al. LUNAR: a randomized phase 2 study of 177lutetium-PSMA neoadjuvant to ablative radiotherapy for oligorecurrent prostate cancer (clinical trial protocol). BJU Int. 132, 65\u201374 (2023).","journal-title":"BJU Int."},{"key":"1144_CR122","doi-asserted-by":"publisher","first-page":"TPS5127","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS5127","volume":"43","author":"AO Sartor","year":"2025","unstructured":"Sartor, A. O. et al. PSMA-delay castration (DC): an open-label, multicenter, randomized phase 3 study of [177Lu]Lu-PSMA-617 versus observation in patients with metachronous PSMA-positive oligometastatic prostate cancer (OMPC). J. Clin. Oncol. 43, TPS5127 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1144_CR123","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.euo.2024.10.014","volume":"8","author":"P Ravi","year":"2025","unstructured":"Ravi, P. et al. Combined fixed-duration systemic treatment and metastasis-directed radiotherapy for oligometastatic hormone-sensitive prostate cancer. Eur. Urol. Oncol. 8, 709\u2013715 (2025).","journal-title":"Eur. Urol. Oncol."},{"key":"1144_CR124","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.euo.2025.04.011","volume":"8","author":"A Giesen","year":"2025","unstructured":"Giesen, A. et al. Direct treatment of all visible tumour in synchronous oligometastatic prostate cancer: total eradication of tumour or the full monty treatment. Eur. Urol. Oncol. 8, 1203\u20131207\u00a0(2025).","journal-title":"Eur. Urol. Oncol."},{"key":"1144_CR125","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-022-01662-7","volume":"39","author":"DK Reyes","year":"2022","unstructured":"Reyes, D. K. et al. Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer. Med. Oncol. 39, 63 (2022).","journal-title":"Med. Oncol."},{"key":"1144_CR126","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.eururo.2024.02.008","volume":"86","author":"NG Nickols","year":"2024","unstructured":"Nickols, N. G. et al. Systemic and tumor-directed therapy for oligometastatic prostate cancer: the SOLAR phase 2 trial in de novo oligometastatic prostate cancer. Eur. Urol. 86, 190\u2013193 (2024).","journal-title":"Eur. Urol."},{"key":"1144_CR127","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03436654 (2026)."},{"key":"1144_CR128","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06320067 (2024)."},{"key":"1144_CR129","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT03784755 (2026)."},{"key":"1144_CR130","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04115007 (2025)."},{"key":"1144_CR131","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT04787744 (2026)."},{"key":"1144_CR132","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06198387 (2024)."},{"key":"1144_CR133","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05223803 (2025)."},{"key":"1144_CR134","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT05209243 (2023)."},{"key":"1144_CR135","unstructured":"US National Library of Medicine. ClinicalTrials.gov https:\/\/clinicaltrials.gov\/study\/NCT06150417 (2025)."},{"key":"1144_CR136","doi-asserted-by":"publisher","first-page":"54","DOI":"10.2967\/jnumed.124.268441","volume":"66","author":"LM Unterrainer","year":"2025","unstructured":"Unterrainer, L. M. et al. Low- and high-volume disease in metastatic hormone-sensitive prostate cancer: from CHAARTED to PSMA PET \u2014 an international multicenter retrospective study. J. Nucl. Med. 66, 54\u201360 (2025).","journal-title":"J. Nucl. Med."},{"key":"1144_CR137","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110618","volume":"202","author":"JH Wang","year":"2025","unstructured":"Wang, J. H. et al. Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic castration-sensitive prostate cancer. Radiother. Oncol. 202, 110618 (2025).","journal-title":"Radiother. Oncol."},{"key":"1144_CR138","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.eururo.2025.07.006","volume":"88","author":"AD Sherry","year":"2025","unstructured":"Sherry, A. D. et al. Continuous androgen deprivation therapy with or without metastasis-directed therapy for oligometastatic prostate cancer: the multicenter phase 2 randomized EXTEND trial. Eur. Urol. 88, 496\u2013509 (2025).","journal-title":"Eur. Urol."},{"key":"1144_CR139","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.euo.2021.10.002","volume":"5","author":"T H\u00f6lscher","year":"2022","unstructured":"H\u00f6lscher, T. et al. Toxicity and efficacy of local ablative, image-guided radiotherapy in gallium-68 prostate-specific membrane antigen targeted positron emission tomography-staged, castration-sensitive oligometastatic prostate cancer: the OLI-P phase 2 clinical trial. Eur. Urol. Oncol. 5, 44\u201351 (2022).","journal-title":"Eur. Urol. Oncol."},{"key":"1144_CR140","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1200\/JCO.2024.42.4_suppl.163","volume":"42","author":"NG Nickols","year":"2024","unstructured":"Nickols, N. G. et al. Systemic and tumor-directed therapy for oligometastatic prostate cancer (SOLAR): a phase II trial for veterans with de novo oligometastatic prostate cancer. J. Clin. Oncol. 42, 163 (2024).","journal-title":"J. Clin. Oncol."},{"key":"1144_CR141","doi-asserted-by":"publisher","unstructured":"Xu, B. et al. Protocol for evaluating the efficacy and safety of radiotherapy for prostate and oligometastatic lesions in patients with low-burden sensitive oligometastatic prostate cancer: an open, exploratory pilot clinical trial. Cancer Control https:\/\/doi.org\/10.1177\/10732748241274595 (2024).","DOI":"10.1177\/10732748241274595"}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01144-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01144-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01144-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T12:02:04Z","timestamp":1790769724000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01144-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,6]]},"references-count":141,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1144"],"URL":"https:\/\/doi.org\/10.1038\/s41585-026-01144-9","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,6]]},"assertion":[{"value":"31 March 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}